Kolexia
Manlay Luc Gastro-entérologie
Manlay Luc
Gastro-entérologie
Centre Medico Chirurgical Tronquieres
Aurillac, France
28 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Maladie de Crohn Maladies inflammatoires intestinales Colite Rectocolite hémorragique Nécrose Rectite Syndrome du côlon irritable Ulcère Fibrose

Collaborateurs

Voir plus
Buisson Anthony
Buisson Anthony
Hôpital Estaing, Clermont-Ferrand, France
Reymond Maud
Reymond Maud
Clinique De La Plaine, Clermont-Ferrand, France
Payen Laure
Payen Laure
Clinique D'argonay, Argonay, France
Collin Rémi
Collin Rémi
Hôpital Dupuytren, Limoges, France

Industries

Voir plus
Janssen
5 collaboration(s)
Dernière en 2022
Abbvie
2 collaboration(s)
Dernière en 2022
Takeda Pharmaceutical
2 collaboration(s)
Dernière en 2023
Ipsen
1 collaboration(s)
Dernière en 2020

Dernières activités

Voir plus
Top-down Versus Step-up Strategies to Prevent Postoperative Recurrence in Crohn's Disease.
Inflammatory bowel diseases   02 février 2023
Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   17 août 2022
P348 Top down versus step-up strategies to prevent postoperative recurrence in Crohn’s disease
Abstracts of the 17th Congress of ECCO Virtual February 16-19, 2022   21 janvier 2022
P400 Evolution of clinical and pharmacological parameters after switching from intra-venous to subcutaneous infliximab in patients with inflammatory bowel disease: the REMSWITCH study
Abstracts of the 17th Congress of ECCO Virtual February 16-19, 2022   21 janvier 2022
Ustekinumab is more effective than azathioprine to prevent endoscopic postoperative recurrence in Crohn's disease.
United European gastroenterology journal   05 mai 2021
Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Alimentary pharmacology & therapeutics   28 avril 2021
P130 Faecal calprotectin is a reliable tool to assess endoscopic activity in ulcerative colitis except for short-extent proctitis
Abstracts of the 15th Congress of ECCO Vienna, Austria, February 12–15, 2020   15 janvier 2020
{{person.lastact8.name}}
{{person.lastact8.jour}}   {{person.lastact8.date}}
{{person.lastact9.name}}
{{person.lastact9.jour}}   {{person.lastact9.date}}
{{person.lastact10.name}}
{{person.lastact10.jour}}   {{person.lastact10.date}}